Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells $37,350.00 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 830 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $45.00, for a total transaction of $37,350.00. Following the sale, the director owned 12,546 shares in the company, valued at $564,570. This represents a 6.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA opened at $43.09 on Friday. The company has a fifty day moving average of $41.81 and a two-hundred day moving average of $38.23. The company has a market capitalization of $3.27 billion, a PE ratio of 95.76 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 1 year low of $18.12 and a 1 year high of $45.50.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). The firm had revenue of $180.86 million during the quarter, compared to analysts’ expectations of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm’s revenue for the quarter was up 61.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.18) earnings per share. On average, research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently made changes to their positions in KNSA. EverSource Wealth Advisors LLC grew its position in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the period. Osaic Holdings Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $31,000. USA Financial Formulas acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $32,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $41,000. Finally, Quantbot Technologies LP acquired a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $43,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on KNSA shares. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Wedbush lifted their price objective on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. The Goldman Sachs Group increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Finally, Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $52.33.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.